Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0294-v1Release info

Latest

Research title

Single cell analysis of tumor-infiltrating T cells

Research overview

Aims
The objective is to analyze tumor and normal cell whole exome sequencing (WES) of esophageal cancer patients participating in the TENERGY-TR before treatment and RNA-seq specimens of tumor biopsy specimens at three points before treatment, after radiation chemotherapy, and after Atezolizumab administration, to search for biomarkers to predict treatment response.
Methods
DNA/RNA was extracted from frozen tumor or blood samples using an AllPrep DNA/RNA Mini kit (Qiagen) at each time point. Whole exome sequencing and RNA sequencing analyses were performed.
Participants/materials
- WES: tumor tissue (27 samples) and normal tissue (27 samples) from esophageal cancer patients
- RNA-seq: tumor biopsy specimens at three-time points before treatment (28 samples), after radiation chemotherapy (25 samples) and after Atezolizumab administration (25 samples)
URL

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000841NGS (Exome, RNA-seq)
  • WES
  • RNA-seq
Controlled-access (Type I)2024-05-29

Data provider

Principal investigator
Shogo Kumagai
Affiliation
Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Research projects

No research projects.

Grants

NameTitleProject number
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)
A phase II, multicenter study to investigate the safety, efficacy, and proof-of-concept (POC) of Anti PD-L1 antibody monotherapy following radical chemoradiotherapy in patients with inoperable locally advanced esophageal squamous cell cancer
  • JP21ck0106420

Related publications

TitleDOIDataset ID
Atezolizumab monotherapy following dCRT indicated a promising cCR rate in patients with unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
https://doi.org/10.1200/jco.2023.41.4_suppl.416 (opens in a new tab)

Controlled access users

Principal investigatorAffiliationCountry/RegionResearch titlePeriod of data useDataset ID
Michiaki HamadaHamada Laboratory, Faculty of Science and Engineering, Waseda UniversityJapanConstruction of RNA-targeted Drug Discovery Database2023-01-05 – 2027-10-31